| Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations (NCT05364073) | ArriVent BioPharma, Inc. | 2022-06-30 |
| Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma (NCT05303493) | Centre hospitalier de l'Université de Montréal (CHUM) | 2022-06-29 |
| A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer (NCT05318573) | Fujifilm Pharmaceuticals U.S.A., Inc. | 2022-06-01 |
| Lifei Xiaoji Wan in Treatment of Advanced NSCLC (NCT06406166) | Henan University of Traditional Chinese Medicine | 2022-06-01 |
| A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer (NCT05215067) | Akeso | 2022-05-13 |
| Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer (NCT05004974) | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 2022-04-26 |
| A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy (NCT05287386) | The First Affiliated Hospital of Xiamen University | 2022-01-21 |
| Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer (NCT04755738) | Qianfoshan Hospital | 2022-01-01 |
| KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent (NCT05001724) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2021-10-28 |
| First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) (NCT05099172) | Bayer | 2021-10-25 |
| Tislelizumab as Cross-line Treatment for Advanced NSCLC (NCT05192681) | Fujian Cancer Hospital | 2021-10-10 |
| Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer (NCT05435274) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2021-09-30 |
| Adoptive TKC Transfer Combined With Chemotherapy for Advanced Non-small Cell Lung Cancer (NSCLC) (NCT04990063) | suhaichuan | 2021-08-08 |
| Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer (NCT04940325) | Gustave Roussy, Cancer Campus, Grand Paris | 2021-05-12 |
| A Phase 1/2 Study of SC-43 in Combination With Cisplatin (NCT04733521) | RaND Biosciences | 2021-05-01 |
| A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer (NCT04818333) | Jiangsu HengRui Medicine Co., Ltd. | 2021-04-23 |
| Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients with NSCLC (NCT04886401) | University Hospital, Brest | 2021-04-16 |
| Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (NCT04685135) | Mirati Therapeutics Inc. | 2021-02-23 |
| Efficacy of Osimertinib in Patients With Lung Cancer (NCT06174857) | Hunan Province Tumor Hospital | 2021-01-01 |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 (NCT04613596) | Mirati Therapeutics Inc. | 2020-12-02 |
| Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer (NCT04263051) | Centre Hospitalier Universitaire de Besancon | 2020-09-09 |
| Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer (NCT04922658) | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 2020-06-03 |
| Bronchoscopic Cryo-Immunotherapy of Lung Cancer (NCT04049474) | NYU Langone Health | 2020-02-15 |
| Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC (NCT04144608) | Yongchang Zhang | 2020-01-16 |
| Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology (NCT03948724) | Institut Cancerologie de l'Ouest | 2019-12-11 |
| ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC (NCT04032847) | Achilles Therapeutics UK Limited | 2019-07-08 |
| Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung Cancer (NCT03727867) | Haihua Yang | 2019-06-01 |
| Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer（NSCLC） (NCT03693547) | Beijing Biostar Pharmaceuticals Co., Ltd. | 2019-04-22 |
| Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation (NCT03856697) | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | 2019-03-01 |
| Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer (NCT04239443) | Hunan Cancer Hospital | 2019-01-30 |
| RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer (NCT03681483) | Memorial Sloan Kettering Cancer Center | 2018-10-31 |
| A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) (NCT03516981) | Merck Sharp & Dohme LLC | 2018-10-01 |
| AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer (NCT03371485) | Cancer Research UK | 2018-05-29 |
| Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients (NCT03351361) | Rennes University Hospital | 2018-02-19 |
| D-0316 First Time in Patients Ascending Dose Study (NCT03452150) | InventisBio Co., Ltd | 2018-01-03 |
| Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC (NCT03326752) | Dynavax Technologies Corporation | 2017-09-20 |
| Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) (NCT03014648) | Liza Villaruz, MD | 2017-07-18 |
| Brain Metabolic Network of PET in Patients With Advanced Non-Small Cell Lung Cancer (NCT05380908) | Fifth Affiliated Hospital, Sun Yat-Sen University | 2017-06-01 |
| Multimodality Treatment Including Curative Resection of Advanced NSCLC (NCT04455984) | Medical University of Vienna | 2017-05-01 |
| Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC. (NCT02964689) | Swiss Cancer Institute | 2017-04-12 |
| Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer (NCT03652857) | Yongchang Zhang | 2017-01-01 |
| Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer (NCT02639234) | Gradalis, Inc. | 2016-03-01 |
| ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer (NCT02582125) | Ono Pharmaceutical Co., Ltd. | 2016-01-27 |
| Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer (NCT02163733) | AstraZeneca | 2014-11-14 |
| Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva) (NCT02157883) | AstraZeneca | 2014-11-06 |
| T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer (NCT02133196) | National Cancer Institute (NCI) | 2014-10-23 |
| AZD9291 in Combination With Ascending Doses of Novel Therapeutics (NCT02143466) | AstraZeneca | 2014-08-05 |
| The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab (NCT02200354) | Kobe City General Hospital | 2014-07-01 |
| A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies (NCT02108964) | Novartis Pharmaceuticals | 2014-06-06 |
| A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer (NCT02038699) | Jazz Pharmaceuticals | 2014-01-01 |
| AZD9291 First Time In Patients Ascending Dose Study (NCT01802632) | AstraZeneca | 2013-03-04 |
| Individualized Treatment of Patients With Advanced NSCLC: Potential Application for Circulating Tumor Cells (CTC) Molecular and Phenotypical Profiling (NCT02407327) | Istituto Oncologico Veneto IRCCS | 2012-12-01 |
| Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer (NCT01631136) | Intergroupe Francophone de Cancerologie Thoracique | 2012-07-01 |
| Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II (NCT01649947) | Rutgers, The State University of New Jersey | 2011-12-23 |
| Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer (NCT03117335) | Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. | 2011-11-10 |
| Study of Participants With Advanced Non-Small Cell Lung Cancer (NCT00948675) | Eli Lilly and Company | 2009-09-01 |
| Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients (NCT01240447) | Laboratorio Elea Phoenix S.A. | 2009-09-01 |
| Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC) (NCT00783471) | Hellenic Cooperative Oncology Group | 2008-11-01 |
| A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) (NCT00874328) | National Cancer Center, Korea | 2008-10-01 |
| Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types (NCT00633789) | Bristol-Myers Squibb | 2008-06-01 |
| Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer (NCT00737867) | The Norwegian Lung Cancer Study Group | 2007-09-01 |
| Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer (NCT00708812) | Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd | 2007-07-01 |
| Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC (NCT00786331) | Gruppo Oncologico Italiano di Ricerca Clinica | 2007-07-01 |
| TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer (NCT00349219) | National Cancer Institute, Naples | 2006-12-01 |
| CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer (NCT00330746) | National Cancer Institute, Naples | 2005-11-01 |
| The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer (NCT00345059) | National Cancer Institute, Naples | 2005-05-01 |
| Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer (NCT00651833) | Taiho Oncology, Inc. | 2005-02-01 |
| Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer (NCT00652561) | Taiho Oncology, Inc. | 2005-02-01 |
| Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling (NCT00161278) | University of Michigan Rogel Cancer Center | 2004-12-01 |
| Weekly Versus 3-Weekly Docetaxel Plus Cisplatin for Advanced NSCLC (NCT00319514) | Gachon University Gil Medical Center | 2004-04-01 |
| Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer (NCT00072631) | OSI Pharmaceuticals | 2003-11-05 |
| Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC (NCT00385606) | National Cancer Institute, Naples | 2003-01-01 |
| Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors (NCT00064636) | Millennium Pharmaceuticals, Inc. | 2002-12-01 |
| Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation (NCT06761976) | Bayer | |